Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
Blood (2008) 111 (4): 1834–1839.
Currently there are no citedby results. Try again later.
